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ABSTRACT 
Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic 
burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and repro-
ducible markers of efficacy are not available for clinical use. Further complicating treatment, the 
diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. 
A number of markers of MDD and antidepressant response have been investigated at the genetic, 
epigenetic, gene expression and protein levels. Polymorphisms in genes involved in anti-depressant 
metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid 
signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included 
in the first pharmacogenetic assays that have been tested for clinical applicability. The results of 
these investigations were encouraging when examining patient-outcome improvement. 
Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-a receptor 
type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. 
These first diagnostic and response-predictive tests for MDD provided a source of optimism for 
future clinical applications. However, such findings should be considered very carefully because their 
benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include 
combinations of different types of biomarkers and be specific for MDD subtypes or pathological 
dimensions.  
1. Introduction 
Major depressive disorder (MDD) was among the five leading diseases contributing to DALYs in 2010 
in the USA, after cardiovascular diseases and lung cancer (Murray et al. 2013). The disorder also 
carries with it a substantial increase in suicide risk (Bradvik et al. 2008), a quality of life comparable 
to that of severe physical disorders such as arthritis and heart disease (Buist-Bouwman et al. 2006) 
and significant health expenditures, with direct costs alone amounting to 42 billion dollars in Europe 
(Sobocki et al. 2006). 
Despite the demonstrated efficacy of antidepressant medications, high inter-individual variability is 
observed in both response and side-effect occurrence and the lack of reliable markers of these 
outcomes contributes to unsatisfactory treatment effectiveness, poor treatment adherence and 
early treatment discontinuation (Fabbri et al. 2013a). Furthermore, few studies include or adjust for 
placebo response, which has been shown to account for 67.6% of the efficacy observed in anti-
depressant treatment (Rief et al. 2009). Placebo response is a major concern for drug trials, as well 
as for biomarker investigations, and likely has a significant genetic component (Walsh et al. 2002; 
Tiwari et al. 2013; Holmes et al. 2016). Importantly, objective criteria are not available to support the 
diagnosis of MDD based on clinical criteria only, resulting in the risk of clinician-dependent variability 
in terms of both diagnosis type and severity. Indeed, two well-known scenarios are observed in 
clinical settings: the diagnosis conflates adaptive sadness reactions with pathological states of 
depressed mood, resulting in overdiagnosis and over-treatment; on the other hand, underdiagnosis 
and undertreatment may lead to a severe, chronic, recur-rent or treatment-resistant course 
(Lorenzo-Luaces 2015). 
Research has been oriented toward the identification of biomarkers of MDD and antidepressant 
treatment outcomes, i.e., genetic or epigenetic variations, measures of gene expression or protein 
levels. Genetic variations that have been investigated in this field are mainly common single-
nucleotide polymorphisms (SNPs). Common SNPs alone have been estimated to explain about 42% 
of the variance in antidepressant response (Tansey et al. 2013). Epigenetics refers to the study of 
phenotypic variations that are not caused by DNA sequence modifications and it includes gene 
methylation and histone modifications. Epigenetic pro-files are inherited but are responsive to 
environmental stress, especially during early development (Jaenisch and Bird, 2003). Indeed, 
exposure to stressful or traumatic life events, especially early in life, is one of the strongest risk 
factors for the development of several psychiatric disorders, including MDD. Gene expression (mRNA 
levels) and protein level measures are useful complementary data to genetic and epigenetic 
information, since several levels of regulation occur after gene translation (i.e., post-translational 
modifications involving addition of functional groups or other proteins/peptides, structural changes, 
catabolic processes). Blood cells represent an easily available sample for gene expression studies and 
they share between 35 and 80% of the transcriptome with the brain (Tylee et al. 2013). A particular 
type of ribonucleic acid (RNA) known as microRNA (miRNA) received attention recently because 
miRNAs function as modulators of the degradation and translation of messenger RNA (mRNA), thus 
they represent a fundamental regulatory step in the process leading to protein production. Proteins 
can be dosed in serum or plasma and different protocols can be applied, thereby showing the results 
of proteomic studies are affected by preanalytical and analytical variability often resulting in poor 
comparability among different studies. Furthermore, new methods for quantitative proteomics were 
recently developed to increase the precision, robust-ness, and resolution of protein measurement (Li 
et al. 2015). 
We emphasise that markers of acute depressive phases (i.e., state markers such as the expression 
level of inflammatory genes) are distinct from markers of susceptibility to MDD (i.e., markers of 
vulnerability to the disease such as genetic variants), but they partially over-lap and are not always 
easy to distinguish. For example the expression level of some genes may be altered especially during 
the acute phases, but it may not completely normalise after symptom remission. The avail-able 
evidence for gene expression levels was mostly obtained during the acute phase of MDD. Finally, the 
aetiopathogenesis of MDD is hypothesised to partially but not completely overlap with the 
mechanisms of antidepressant drug action, thus the sections discussing the markers of 
antidepressant efficacy have been separated from those discussing the markers of MDD. 
2. Methods 
The present review is focused on biomarkers of MDD and antidepressant responses that may be 
nearest to clinical applications, i.e., biomarkers that: 
1. have an association with the phenotypes of interest at several ‘‘omics’’ levels (genetic, 
epigenetic and/or peripheral blood transcriptomics/proteomics); 
2. are supported by at least one meta-analysis or replicated results in the same direction by at 
least three studies in conjunction with consistent data from translational studies. 
In addition to these criteria, biomarkers that have been included in a pilot study testing clinical 
applicability (in terms of individual and possibly economic benefits) are also included in this review. 
For an overview of markers in the first and second group see Tables 1 and 2, respectively. 
Finally, a section is dedicated to new promising bio-markers, including miRNAs and, for example, 
methodological approaches such as polygenic risk scores (PRS). The data used for this review have 
been extracted from MEDLINE, EMBASE and Web of Science (ISI) and include articles published up to 
February 2016. 
3. Serotonergic neurotransmission 
Serotonin (5-HT) is known to be involved in many physiological and behavioural processes that are 
dysregulated in MDD, including mood, appetite, sleep, activity, suicide, sexual behaviour and 
cognition. The decreased levels of 5-HT metabolites in cerebrospinal fluid (CSF), coupled with the 
mood-lowering effects of tryptophan depletion and the efficacy of serotonin-modulating 
antidepressants, have supported the theory that dysfunctions of the 5-HT system are involved in the 
pathogenesis of MDD (Jans et al. 2007). Genetic polymorphisms are among the innate factors that 
modulate 5-HTergic neurotransmission, given that heritability has been reported to account for 
approximately 35% of the variance in CSF 5-hydroxyindoleace-tic acid (5-HIAA), the main metabolite 
of 5-HT levels (Beck et al. 1984; Oxenstierna et al. 1986). 
3.1. Serotonin transporter 
The serotonin transporter (SERT) is the primary target of selective serotonin reuptake inhibitors 
(SSRIs) and one of the main targets of other antidepressant classes. The SERT is responsible for 5-HT 
reuptake from the synaptic cleft and thus determines the magnitude and duration of the 5-HT 
synaptic signal. A reduction of SERT sites in the brain (particularly in midbrain and amygdala) of 
depressed patients has been demonstrated both by functional imaging (Gryglewski et al. 2014; Yeh 
et al. 2014) and post-mortem brain studies (Mann et al. 2000). As the binding to the SERT and the 5-
HT uptake capacity remain low after recovery, low SERT activity has been suggested as a trait marker 
for mood disorders (Lesch 2001). 
3.1.1. Genetic polymorphisms 
Known polymorphisms in the gene coding for the SERT (SLC6A4) produce alterations in the 
expression level and are hypothesised to affect both the risk of affective disorders and 
antidepressant response. In detail, the short (S) allele (14-repeats) of the 5-HTTLPR 
insertion/deletion polymorphism determines a half basal expression of SERT compared to the long 
(L) allele (16-repeats) (Heils et al. 1996), as well as when compared to the L allele combination with 
the G allele of the rs25531 polymorphism (LG) (Hu et al. 2006). A number of genetic studies 
investigated the effect of the 5-HTTLPR polymorphism on susceptibility to MDD, and two meta-
analyses reported absent or negligible effects (Munafo et al. 2009; Risch et al. 2009). However, these 
meta-analyses included only a minority of the available studies. A more recent and comprehensive 
study found strong evidence that 5-HTTLPR moderates the relationship between stress and 
depression, with an association between the S allele and the risk of developing depression under 
stress (Karg et al. 2011). Stratification of the analysis for the type of stressor showed a stronger risk 
effect of the S allele in cases of childhood maltreatment and medical conditions. A more recent 
study on a cohort of 5,249 individuals assessed at birth and followed up to the age of 18 confirmed 
this gene ฀ environment interaction (Rocha et al. 2015). The interactive effect of the S allele and 
stress on the risk of MDD may be partly explained by the modulation of the hypothalamopituitary-
adrenal (HPA) axis. Indeed, S allele carriers display increased basal activity of the HPA axis and S/S 
homozygotes show increased cortisol/corticosterone stress reactivity compared with L carriers (van 
der Doelen et al. 2014). Interesting findings from imaging studies include smaller hippocampal 
volumes in S carriers with a history of environmental adversities and higher amygdala activity in 
response to a number of negative stimuli in S carriers (Won and Ham, 2016). In conclusion, the 5-
HTTLPR S allele is considered to be a risk factor for MDD but only in cases of stressful environmental 
conditions and it is neither a required nor sufficient factor for developing MDD. Insufficient data are 
available in regard to the role of the triallelic locus (5-HTTLPR and rs25531 combination) in MDD 
susceptibility (Odgerel et al. 2013). 
 
The triallelic 5-HTTLPR/rs25531 locus was also extensively investigated as a modulator of 
antidepressant response. Single-photon emission computed tomography and positron emission 
tomography (PET) studies reported that higher pre-treatment availability and greater SSRI 
occupancy of the SERT might predict better treatment response (Kugaya et al. 2004; Yeh et al. 2015). 
The most confirmed pharmacogenetic finding was an association of the S allele with worse 
antidepressant efficacy than the LL genotype in Caucasian patients treated with SSRIs (Porcelli et al. 
2012). Relatively fewer studies genotyped the triallelic locus and they did not support a substantial 
role of the polymorphism on antidepressant efficacy (Fabbri et al. 2013a). Several pharmacogenetic 
studies (Perlis et al. 2003; Murphy et al. 2004; Popp et al. 2006; Hu et al. 2007; Smits et al. 2007; 
Maron et al. 2009) and one meta-analysis (Kato and Serretti 2010) reported that the S allele may 
also be a risk factor for the development of SSRI-induced side effects in Caucasian populations, 
though not for sexual dysfunction (Bishop et al. 2009; Strohmaier et al. 2011). 
3.1.2. Gene methylation 
DNA methylation profiles at CpG (cytosine-guanine dinucleotides) islands have been studied as a 
modulator of SLC6A4 expression. Indeed, methylation at CpG islands make a gene less accessible to 
the molecular transcriptional apparatus that decodes the DNA sequence into mRNA and hence the 
production of specific proteins is reduced. An early study found a trend of association between 
history of MDD and increased SLC6A4 methylation (Philibert et al. 2008), and a subsquent study 
reported that depressive symptoms were more common among adolescents with elevated SLC6A4 
methylation who carried the 5-HTTLPR S allele (Olsson et al. 2010). Higher SLC6A4 promoter 
methylation in subjects with a history of childhood adversities was demonstrated (Kang et al. 2013b; 
Booij et al. 2015) and associated with family history of depression and more severe depressive 
psychopathology (Kang et al. 2013b). Another recent study found no evidence of an effect of 
increased SLC6A4 methylation status on the risk of MDD (Okada et al. 2014). These findings support 
the hypothesis that SLC6A4 methylation status may be a proxy of childhood adversities (other than a 
hereditary factor) and thus it may be a useful marker of MDD susceptibility in combination with the 
5-HTTLPR S allele. SLC6A4 methylation status was also investigated in relation to antidepressant 
treatment response, but with mixed results (Kang et al. 2013b; Domschke et al. 2014; Okada et al. 
2014). 
 
3.1.3. Peripheral biomarkers 
The genetic and epigenetic modulation of SERT expression and function has been complemented by 
the study of SERT as a peripheral biomarker of MDD and antidepressant efficacy. SERT functioning 
can be studied in platelets, since the SERT protein expressed in platelets is considered identical to 
the one found in neurons, with similar structural and functional proper-ties found in both tissues 
(Yubero-Lahoz et al. 2013). Higher SERT affinity constant and higher maximal uptake rate before and 
after antidepressant treatment were associated with treatment efficacy (Rausch et al. 2001, 2002, 
2003; Myung et al. 2013). Interestingly, reductions in peripheral cell 5-HT uptake rates, cell sur-face 
SERT binding, and 5-HIAA/serotonin ratios were associated with the 5-HTTLPR S allele, suggesting 
that they may represent proxy markers of the 5-HTTLPR genotype (Singh et al. 2012). SLC6A4 
expression (mRNA level) in peripheral cells (lymphocytes) was also investigated, since lymphocytes 
are thought to potentially act as a neural probe for studying psychiatric dis-orders (Gladkevich et al. 
2004). Studies on small samples of depressed patients suggested a reduction of SERT expression 
after antidepressant treatment (Iga et al. 2005; Tsao et al. 2006) with a possible positive correlation 
with response (Belzeaux et al. 2014), but opposite findings also exist (Pena et al. 2005; Belzeaux et 
al. 2010). The reduction of SERT expression in the rat brain was associated with antidepressant-like 
behaviours (Thakker et al. 2005) and key markers of antidepressant action: reduced expression and 
function of 5-HT1A-autoreceptors, elevated extracellular 5-HT in the forebrain and increased 
neurogenesis and expression of plasticity-related genes (BDNF, VEGF, ARC)in the hippocampus 
(Ferres-Coy et al. 2013). No clear association between SLC6A4 expression and MDD risk was 
demonstrated, since the few studies reported either negative findings (Belzeaux et al. 2010), higher 
expression of the gene in patients compared to controls (Iga et al. 2005) or the opposite finding 
(Pena et al. 2005). 
3.2. Serotonin receptors 
3.2.1. Serotonin receptor 1A 
The 5-HT1A autoreceptor mediates the inhibition of serotonergic raphe neurons by negative 
feedback (Pineyro and Blier 1999), while 5-HT1A postsynaptic receptor activation has been shown to 
increase dopa-mine release in the medial prefrontal cortex (PFC), striatum and hippocampus 
(Sakaue et al. 2000). These findings suggest that increased 5-HT1A presynaptic and decreased 
postsynaptic activity may co-occur in MDD. Several studies using PET imaging demonstrated 
elevated 5-HT1A binding in the brain of MDD subjects, especially in the raphe (Parsey et al. 2010; 
Kaufman et al. 2015). 5-HT1A density distinguished male controls from depressed males with high 
sensitivity and specificity (both >80%) (Kaufman et al. 2015). A reduction in raphe 5-HT1A 
autoreceptor binding was demonstrated during SSRI treatment and was associated with symptom 
improvement (Gray et al. 2013). 
3.2.1.1. Genetic polymorphisms The G allele of a functional promoter polymorphism in the 
serotonin 1A receptor gene (HTR1A rs6295 or C-1019G) has been associated with increased 5-HT1A 
expression in raphe nucleus neurons both in vitro (Lemonde et al. 2003) and in vivo using PET 
(Parsey et al. 2010). A recent meta-analysis found that MDD patients had higher frequencies of the 
GG genotype and/or G allele than controls, confirming the hypothesis derived from func-tional 
studies. The study also found that rs878567 (syn-onymous SNP located downstream of the gene) T 
allele was associated with MDD susceptibility (Kishi et al. 2013). The most recent meta-analyses that 
inves-tigated the role of rs6295 in antidepressant efficacy provided negative findings (Zhao et al. 
2012; Niitsu et al. 2013). Other polymorphisms in the gene were marginally investigated. 
3.2.1.2. Peripheral biomarkers Higher platelet HTR1A expression was associated with MDD and 
severity of symptoms in drug-free patients (Zhang et al. 2014), and higher receptor binding was 
found in lymphocytes of depressed patients (Gonzalez et al. 2007). In contrast, a previous study did 
not report any difference in lymphocyte 5-HT1A receptor capacity and affinitybetween MDD 
patients and controls (Fajardo et al. 2003). No data are available in regard to antidepres-sant 
efficacy. 
3.2.2. Serotonin receptor 2A 
The serotonin receptor 2A (5-HT2A) is primarily a post-synaptic excitatory receptor, with wide 
distribution throughout the brain but with the highest density in the neocortex (Burnet et al. 1995). 
Both depression and suicide have been associated with greater 5-HT2A receptor binding in PFC, 
although data were not consistent (Stein et al. 2007). Accordingly, there is a decrease in 5-HT2A 
binding in cortical regions, particularly in the frontal cortex, after antidepressant treatment (Meyer 
et al. 2001), and compensatory downregulation of 5-HT2A receptors can prevent depressive 
symptoms induced by tryptophan depletion (Yatham et al. 2001). 
3.2.2.1. Genetic polymorphisms Different polymorphisms (rs6311 or -1438A/G, rs6313 or 102C/T, 
rs7997012 and rs7333412) have been investigated within the 5-HT2A gene with several positive but 
often inconsistent findings (Polesskaya and Sokolov 2002; Lin et al. 2009; Fabbri et al. 2013b; Niitsu 
et al. 2013; Zhao et al. 2014). Interestingly, the region downstream to the first intron of the gene 
was found to harbour other possibly relevant polymorphisms in the context of anti-depressant 
response. Indeed, rs7333412, rs7324017, rs1923882 (Fabbri et al. 2014) and rs7997012 (Peters et al. 
2009) are located in this region and were associated with antidepressant response in the STAR*D 
sample. Several other studies investigated rs7997012 with negative results (Illi et al. 2009; Kishi et al. 
2009; Perlis et al. 2009; Uher et al. 2009; Horstmann et al. 2010), although none of these included 
samples as large as the STAR*D study. The effect of rs7997012 and rs6313 on antidepressant 
efficacy was confirmed by the most recent meta-analysis (Lin et al. 2014). 
3.2.2.2. Peripheral biomarkers Platelet 5-HT2A binding kinetics did not differ between MDD patients 
and controls (Khait et al. 2005), but seasonal variation in plate-let 5-HT2A binding was demonstrated 
to be different in MDD patients compared to controls (Khait et al. 2002). Increased density of 
platelet 5-HT2A receptors may be a marker of MDD, but is more consistently associated with suicide 
risk (Mendelson, 2000). Despite increased receptor density, blunted receptor response was found in 
patients who have made high-lethality suicide attempts (Malone et al. 2007). Preliminary evidence 
suggested that a trend of increased HTR2A mRNA levels in peripheral lymphocytes may be observed 
during the first 8 weeks of antidepressant treatment (Belzeaux et al. 2010), suggesting that further 
studies should investigate this potential biomarker of antidepressant efficacy. Another preliminary 
study found that 5-HT2A receptor clustering in peripheral lymphocytes is altered in MDD and may be 
a bio-marker of therapeutic efficacy (Rivera-Baltanas et al. 2014). 
4. Neuroplasticity 
Neural plasticity may be defined as the ability of neurons and neural elements to adapt in response 
to intrinsic and extrinsic signals. Adult neurogenesis, the development of dendritic spines, and 
synaptic adaptations are included among the processes defined as neural plasticity. Adult 
hippocampal neurogenesis has been hypothesised to play a key role in the pathogenesis and 
successful treatment of MDD (Wainwright and Galea 2013). Indeed, depressed patients have 
reduced hippocampal volume and neurogenesis that is influ-enced by the number of episodes and 
duration of the illness (McKinnon et al. 2009; Wainwright and Galea 2013). Antidepressant drugs can 
both prevent stress-induced decrease of hippocampal neurogenesis and reverse it (Malberg and 
Duman 2003; Bessa et al. 2009). Pathway analysis confirmed the enrichment of neuroplasticity 
pathways in MDD, with the involvement of CREB signalling in neurons, synaptic long-term 
potentiation and axonal guidance signalling (Jia et al. 2011; Hunter et al. 2013). Interestingly, several 
members of the integrin signalling pathway, including ITGB3, ZYX, ARF1, CAPNS1, CDC42, ILK, LIMS1, 
RAC2 and TTN were found differentially expressed between antidepressant responders and non-
responders. Integrins are involved in the control of synaptic plasti-city and long-term potentiation 
(Martins-de-Souza et al. 2014). 
4.1. Brain-derived neurotrophic factor 
Brain-derived neurotrophic factor (BDNF) is included in the neurotrophin family of growth factors 
and acts as an important mediator of neuron survival, neuroplasticity and neurogenesis. BNDF is 
implicated in processes that modulate learning, memory and mood (Soule et al. 2006; Cowansage et 
al. 2010). Stress was demonstrated to decrease BDNF in mouse hippocampus, cortical and 
subcortical regions (Pizarro et al. 2004). Antidepressant treatment increases BDNF levels, stimulates 
neurogenesis and reverses the inhibitory effects of stress, thus BDNF and neurotrophins are possible 
targets for developing new antidepressant molecules (Masi and Brovedani 2011). 
4.1.1. Genetic polymorphisms 
The common SNP rs6265 (Val66Met or 196G/A) of the BDNF gene has received particular attention, 
since the Met allele decreases the processing and release of BDNF and is associated with decreased 
hippocampal volume in humans. However, available data do not support a significant effect of 
rs6265 on MDD susceptibility, as indicated by meta-analyses (Gratacos et al. 2007; Gyekis et al. 
2013) that also provided negative findings for other BDNF SNPs (11757C/G, 270T/C, 712A/G and 
rs988748). Conversely, the rs6265 Met allele was demonstrated to moderate the relationship 
between life stress and depression (Hosang et al. 2014; Gutierrez et al. 2015). 
Pharmacogenetic studies of antidepressant response mainly found a positive molecular heterosis 
effect of the rs6265 SNP. Indeed, the rs6265 heterozygous genotype was associated with better 
treatment outcome as confirmed by a recent meta-analysis (Niitsu et al. 2013), although some 
inconsistent or negative findings were also reported (Fabbri et al. 2013a). 
4.1.2. Gene methylation 
Hypermethylation of the BDNF gene promoter was reported in Wernicke’s area (Keller et al. 2010) 
and peripheral blood (Kang et al. 2013a) of subjects who com-mitted suicide. The CpG island of the 
BDNF gene upstream of exon I was found as a possible diagnostic biomarker of MDD (Fuchikami et 
al. 2011), and higher methylation status of the BDNF promoter was associated with MDD (D’Addario 
et al. 2013; Carlberg et al. 2014; Dell’Osso et al. 2014; Januar et al. 2015) and post-stroke depression 
(Kim et al. 2013). 
Lower histone 3 lysine 27 (H3K27) trimethylation binding within the BDNF promoter (P4 region) of 
PFC (Chen et al. 2011) and peripheral blood (Lopez et al. 2013) was associated with antidepressant 
treatment, and with positive response to treatment (Lopez et al. 2013). The effect of antidepressant 
drugs on BDNF promoter methylation levels is still scarcely investigated and available data suggested 
a possible higher methylation status in treated versus untreated patients (Carlberg et al. 2014), but 
an enhanced reduction in suicidal ideation after treatment in subjects with low methylation levels 
(Kang et al. 2013a). Methylation levels may also be reduced in patients receiving combination 
treatments of antidepressants plus mood stabilisers compared to patients on antidepressant drugs 
alone (D’Addario et al. 2013). 
4.1.3. Peripheral biomarkers 
According to recent meta-analytic results, both serum and plasma BDNF levels are decreased in 
acute MDD, but do not differ in euthymic subjects with a history of MDD compared to healthy 
controls. Furthermore, anti-depressant treatment of MDD patients increases serum BDNF levels in 
responders and remitters significantly more than in non-responders, but insufficient data are 
available for comparing plasma levels in responders versus non-responders (Polyakova et al. 2015). 
This would be an important comparison, as plasma and serum BDNF levels show at least a 100-fold 
difference (Rosenfeld et al. 1995). The results of prior meta analyses reported similar results. Their 
analyses demonstrated lower serum BDNF concentrations in antidepressant-free depressed patients 
relative to both healthy controls and antidepressant-treated depressed patients (Brunoni et al. 2008; 
Molendijk et al. 2014) and an increase in BDNF levels after antidepressant treatment that was 
associated with the degree of symptom improvement (Brunoni et al. 2008). 
4.2. Cyclic AMP response element binding protein 1 
Cyclic AMP response element binding protein 1 (CREB1) encodes a transcription factor that induces 
transcription of genes in response to hormonal stimulation of the cAMP pathway. Chronic treatment 
with SSRIs increased the expression of phosphorylated CREB1 in the hippocampus and PFC of rats, 
and treatment with antidepressants also increased the levels of protein and mRNA of CREB1 and 
BDNF in the hippocampus of rats (Ignacio et al. 2014). As a result of such findings, CREB1 is 
hypothesised to upregulate the transcription of BDNF, representing an important mechanism of 
action of antidepressants. 
4.2.1. Genetic polymorphisms 
CREB1 polymorphisms have been associated with mood disorders, mainly exhibiting a significant 
gender effect (Zubenko et al. 2003a, 2003b; Perlis et al. 2007; Dong et al. 2009; Utge et al. 2010; 
Juhasz et al. 2011; Lazary et al. 2011), nevertheless not unequivocally (Burcescu et al. 2005; Hettema 
et al. 2009). Findings for CREB1 and antidepressant response are also inconsistent (Murphy et al. 
2004; Wilkie et al. 2007; Serretti et al. 2011; Calati et al. 2013) and negative findings have also been 
reported (Dong et al. 2009; Crisafulli et al. 2012; Matsumoto et al. 2014). 
4.2.2. Peripheral biomarkers 
CREB DNA binding activity, CREB total protein expression and phosphorylated CREB were found 
decreased in leukocytes of drug-free MDD patients compared with normal controls (Ren et al. 2011; 
Lim et al. 2013). On the other hand, no difference in mRNA levels between patients and controls was 
demonstrated by other studies in small samples of MDD patients (Lai et al. 2003; Belzeaux et al. 
2010; Iacob et al. 2013). Another study focussed on mRNA levels in leukocytes demonstrated an 
opposite finding, i.e., higher CREB mRNA levels in MDD patients compared to controls (Iga et al. 
2007). We underline that negative findings were restricted to gene expression studies that did not 
consider CREB DNA binding activity and protein levels, and were therefore unable to identify 
possible consequences of abnormalities during or after mRNA translation into proteins. 
Animal models (Tardito et al. 2009) and in vitro data (Hisaoka et al. 2008) support the induction of 
CREB activation and CREB-regulatory signalling by antidepressants. Patients with low baseline 
phosphorylated CREB in peripheral T lymphocytes showed a greater rate of response than patients 
with high baseline phosphorylated CREB. A value of baseline phosphorylated CREB for predicting 
response was identified by Hisaoka et al. (2008) who reported a positive predictive value of 0.78, a 
negative predictive value of 0.64 and accuracy of 0.695. After 6 weeks of SSRI treatment, median 
values of change of both total and phosphorylated CREB were greater in responders than in non-
respond-ers (Lim et al. 2013). A greater increase in phosphorylated CREB in responders was 
confirmed by other studies using different pharmacological or psychotherapeutic treatments (Koch 
et al. 2002, 2009), but no variation was reported after venlafaxine treat-ment (Rojas et al. 2011). 
Inconsistent findings were reported in regard to CREB1 mRNA variations after antidepressant 
treatment (increased, Belzeaux et al. 2010, or decreased, Lai et al. 2003; Iga et al. 2007, levels). 
4.3. Glial cell line-derived neurotrophic factor 
Glial cell line-derived neurotrophic factor (GDNF) is a member of the transforming growth factor 
beta super-family and is extensively distributed in mammalian brains, including the hypothalamus, 
substantia nigra and thalamus (Golden et al. 1998). GDNF promotes neurite growth (Ducray et al. 
2006) and protects neurons and glial cells from oxidative or neuro-inflammatory injury (Hochstrasser 
et al. 2011; Jaumotte and Zigmond 2014). 
4.3.1. Genetic polymorphisms 
To the best of our knowledge, only one previous study investigated the possible impact of GDNF 
genetic poly-morphisms on antidepressant response and no study investigated the possible effect on 
MDD susceptibility. In detail, rs2973049 A allele and rs2216711 T allele were associated with 
paroxetine non-response in a Chinese population (Wang et al. 2014), the latter showing a selective 
effect in females. 
4.3.2. Peripheral biomarkers 
Recent meta-analytic findings supported a moderate but significant decrease in serum GDNF protein 
level in patients with depression, with a selective effect on MDD that was not observed in other 
depressive disorders nor in old-age depression (Lin and Tseng 2015). A decrease in serum GDNF 
protein level was also found in adolescent depression (Pallavi et al. 2013), but meta-analytic data are 
unavailable to support this finding. GDNF mRNA in peripheral cells was reduced in individuals during 
a major depressive episode compared to individuals in remission and to healthy controls (Otsuki et 
al. 2008). Furthermore, an increase in serum GDNF concentrations was demonstrated after 
antidepressant pharmacological treatment (Zhang et al. 2008) and electroconvulsive therapy (Zhang 
et al. 2009). 
5. Inflammation and HPA axis 
Bi-directional mechanisms have been hypothesised to link inflammatory processes and depression. 
Prolonged exposure to inflammatory mediators can impair the regulation of neuroendocrine 
response to stress, influence the availability of monoamine neurotransmitters, and decrease 
neurogenesis. Conversely, both medically ill and medically healthy patients with MDD have been 
found to exhibit elevations in inflammatory cytokines and their soluble receptors in peripheral blood 
and CSF, as well as elevations in peripheral blood concentrations of acute phase proteins, 
chemokines, adhesion molecules and inflammatory mediators such as prostaglandins (Miller et al. 
2009). A proteomic analysis in patients with MDD compared to controls confirmed that altered 
expression proteins involve lipid metabolism and inflammation (Xu et al. 2012). A comprehensive 
analytical framework based on multiple lines of evidence including association, linkage, gene 
expression, regulatory pathways and literature searches further support the role of inflammatory 
pathways in MDD (Jia et al. 2011). 
5.1. C-reactive protein 
C-reactive protein (CRP) is a marker of systemic inflammation and CRP phenotypes are ฀40% 
heritable, a hereditability similar to that for major depression (Su et al. 2009). Environmental factors 
such as smoking, obesity and cardiovascular diseases, as well as gender differences could also be 
implicated and modulate the relationship between the CRP gene and depression (Hage and Szalai 
2009). This may be especially import-ant in the elderly who have a high prevalence of comorbid 
chronic disorders. 
5.1.1. Genetic polymorphisms 
Several genetic polymorphisms in the CRP gene have been associated with CRP levels (Almeida et al. 
2009), but their association with depression remains controversial (Almeida et al. 2009; Halder et al. 
2010; Luciano et al. 2010; Gaysina et al. 2011; Ancelin et al. 2015). 
5.1.2. Peripheral biomarkers 
High CRP serum levels were identified as a risk factor for de novo depression in women (Pasco et al. 
2010), depression in men (Ford and Erlinger, 2004; Liukkonen et al. 2006; Elovainio et al. 2009; 
Vogelzangs et al. 2012), atypical depression (Hickman et al. 2014) and depressive symptoms (Uddin 
et al. 2011), especially of the somatic type (Duivis et al. 2013). Furthermore, life-time occurrence of 
multiple depressive episodes was associated with higher CRP levels (Copeland et al. 2012). In a very 
large cohort of more than 70, 000 individuals, cross-sectional analysis demonstrated that increased 
CRP levels were associated with increased risk for psychological distress and depression (Wium-
Andersen et al. 2013). Two meta-analyses have con-firmed that major depression is associated with 
increased CRP levels (Howren et al. 2009; Valkanova et al. 2013). 
The majority of studies demonstrated a reduction in CRP serum level after SSRI treatment (Leo et al. 
2006; O’Brien et al. 2006; Pizzi et al. 2009) and treatment with non-SSRI antidepressants (Lanquillon 
et al. 2000; Tuglu et al. 2003). A single study reported opposite findings (Dawood et al. 2007). A 
meta-analysis reported a marginally significant decrease in CRP after anti-depressant treatment 
(Hiles et al. 2012), while higher CRP levels at baseline were found to predict the persistence of 
depressive symptoms over 5 years (Zalli et al. 2015). Interestingly, MDD patients with high CRP levels 
were also reported to be less placebo-responsive and less responsive to eicosapentaenoic acid (EPA; 
Rapaport et al. 2015). 
5.2 Interleukin-1b 
Interleukin-1b (IL-1b) is a potent pro-inflammatory cytokine that acts as a key driver of both 
peripheral and central immune responses. IL-1b has been extensively described for its ability to act 
within the CNS as a modulator of hippocampal memory, as well as for its involvement in neuronal 
death (van de Veerdonk and Netea 2013). IL-1b was demonstrated to regulate the activity of key 
members of the kynurenine pathway with an effect on the availability of tryptophan and the 
production of toxic metabolites, explaining its modulaing effect on neurogenesis in human 
hippocampal pro-genitor cells (Zunszain et al. 2012). 
5.2.1. Genetic polymorphisms 
The G allele of the rs16944 polymorphism (located within the promoter of the IL-1b gene) has been 
associated with SSRI non-response (Yu et al. 2003; Tadic et al. 2008; Baune et al. 2010) and with 
recurrent major depression (Borkowska et al. 2011). In addition, IL-1b promoter polymorphism 
rs1143627 was also associated with recurrent major depression (Borkowska et al. 2011). 
5.2.2. Peripheral biomarkers 
Meta-analyses reported both a positive association between IL-1b serum level and depression 
(Howren et al. 2009), in addition to a reduction in IL-1b serum level following antidepressant 
treatment (Hannestad et al. 2011). However, one meta-analysis investigated the role of IL-1b serum 
level in major depression and reported no evidence of association (Dowlati et al. 2010). The latter 
meta-analysis included fewer studies compared to the work of Howren et al. (2009) though the 
study did take into account potential confounders (e.g., BMI, type of depression assessment). More 
recent studies found that serum levels of IL-1b were higher in MDD when compared to controls or 
bipolar disorder subjects (Mota et al. 2013) and IL-1b mRNA was identified as a possible marker for 
predicting antidepressant response (Belzeaux et al. 2012). The latter finding was confirmed by an 
independent study that found higher baseline mRNA levels of IL-1b (þ33%) in non-responders 
(Cattaneo et al. 2013). Platelet content of IL-1b was also associated with MDD (Hufner et al. 2014). 
5.3. Interleukin-6 
Interleukin-6 (IL-6) is a pleiotropic pro-inflammatory cytokine, whose peripheral concentration was 
found to be inversely related to hippocampal volume in MDD (Frodl et al. 2012). The pathogenetic 
role of IL-6 in depression involves the acute phase of response, disorders in zinc and the erythron, 
HPA axis activation, induction of the tryptophan catabolite pathway, oxidative stress, autoimmune 
processes and neuroprogression (Maes et al. 2014). 
5.3.1. Genetic polymorphisms 
IL-6 polymorphisms were mainly studied in relation to specific subtypes of depression, such as post-
stroke depression (Kim et al. 2012) and childhood depression (Misener et al. 2008), but with 
negative findings. The -174 SNP (rs1800795) is particularly interesting since individuals who carry the 
G allele have higher plasma concentrations of IL-6 (Zakharyan et al. 2012) and the polymorphism has 
been studied as a modulator of interferon-induced depression. Patients who carried the C allele (low 
synthesising IL-6) were reported to show fewer depressive and anxiety symptoms than those 
carrying the G allele, after beginning treatment with IFN-a (Bull et al. 2009; Udina et al. 2013). 
However, only a small study investigated the potential role of the SNP in MDD and it reported 
negative findings (Clerici et al. 2009), while an additional study reported no association between 
MDD and the SNP at -634 in a Chinese population (Hong et al. 2005). Our findings suggest further 
investigation of IL-6 polymorphisms in MDD is warranted, particularly as a suggestive signal 
(rs7801617 SNP) for association with escitalopram response was detected in the IL-6 gene in the 
Genome-Based Therapeutic Drugs for Depression (GENDEP) genome-wide association study (Uher et 
al. 2010). 
5.3.2. Gene methylation 
An inverse correlation between methylation of IL-6 CpGs and circulating IL-6 and CRP levels was 
reported in individuals with lifetime depression (Uddin et al. 2011), but findings have yet to be 
replicated. 
5.3.3. Peripheral biomarkers 
Two meta-analyses supported the association between MDD and higher IL-6 levels compared to 
healthy controls (Howren et al. 2009; Liu et al. 2012). Furthermore, one meta-analysis of longitudinal 
studies reported a modest effect of IL-6 levels on the risk of developing subsequent depressive 
symptoms (Valkanova et al. 2013). A pathway analysis on transcriptomic data showed that genes 
upregulated in MDD subjects com-pared to controls were enriched in IL-6 signalling path-ways 
(Jansen et al. 2016). 
Meta-analytic results also suggested a significant decrease in IL-6 serum levels after antidepressant 
treatment (Hiles et al. 2012), as confirmed by a subsequent study that demonstrated a correlation 
between plasma IL-6 levels and changes in severity of depressive state during SSRI treatment 
(Yoshimura et al. 2013). MDD patients with high IL-6 levels were also reported to be less placebo 
responsive and less responsive to EPA (Rapaport et al. 2015). IL-6 mRNA levels at baseline or after 
antidepressant treatment were not found to be associated with response in the GENDEP project 
(Cattaneo et al. 2013; Powell et al. 2013). 
5.4. Tumor necrosis factor alpha 
Tumor necrosis factor alpha (TNF-a) is a pro-inflammatory cytokine that is hypothesised to 
contribute to the development of MDD and is involved in the modulation of serotonergic 
neurotransmission through the increase of SERT expression and activity (Malynn et al. 2013). Mice 
susceptible to stress-induced anhedonia show elevated expression of TNF-a and SERT in the 
prefrontal area (Couch et al. 2013) and SSRIs inhibit the secretion of TNF-a in human T lymphocytes 
(Taler et al. 2007). 
5.4.1. Genetic polymorphisms 
The G-308A (rs1800629) TNF-a polymorphism is a functional SNP whose A allele is associated with 
higher gene expression. Consistent with the inflammatory theory of depression, the A allele was 
associated with a higher risk of MDD in Korean subjects (Jun et al. 2003), but later studies either 
found no association with post-stroke depression (Kim et al. 2012) and single-episode depression 
(Haastrup et al. 2012), or reported a positive association in the opposite direction in late-life 
depression (Cerri et al. 2009). However, these studies were performed on small sample sizes and 
limited coverage of genetic variability was provided. Importantly, the Genetic Association 
Information Network genome-wide association study (1738 cases and 1802 controls) found the 
rs76917 variant showed the strongest evidence of association with MDD (Bosker et al. 2011), 
suggesting that studies with adequate sample size and sufficient gene coverage have increased 
power to demonstrate the influence of TNF-a on MDD. No pharmacogenetic studies are avail-able 
investigating the possible association between TNF-a polymorphisms and antidepressant response. 
5.4.2. Peripheral biomarkers 
Meta-analytic results reported that TNF-a blood levels are higher in MDD compared to healthy 
controls (Dowlati et al. 2010; Liu et al. 2012), especially in sub-jects of European ancestry (Liu et al. 
2012). TNF-a mRNA levels in peripheral leukocytes were also found to be higher in patients with 
major depression com-pared to controls (Tsao et al. 2006). 
Higher baseline levels of TNF-a mRNA and protein were associated with non-response in the 
GENDEP project (Cattaneo et al. 2013; Powell et al. 2013) and findings in the inflammatory cytokine 
pathway at baseline and after antidepressant treatment were found to be targets of TNF (Powell et 
al. 2013). TNF-a mRNA levels at baseline were proposed as predictive of antidepressant response in 
conjunction with three other mRNAs (PPT1, IL-1b and HIST1H1E) (Belzeaux et al. 2012). A meta-
analysis antecedent to these studies found no clear evidence of reduction in TNF-a serum levels after 
antidepressant treatment, but found some evidence that SSRIs may reduce TNF-a serum levels 
(Hannestad et al. 2011). 
5.5. FK506-binding protein 52 or 51 
The FKBP5 (FK506-binding protein 52 or FKBP51) gene encodes for a member of the family of large 
immunophilins. The encoded protein was reported to act as a scaffolding protein regulating Akt 
activity that might have implications in the development and treatment of depression (Duman and 
Voleti 2012). The FKBP51 protein is a co-chaperone for glucocorticoid receptor (GR) maturation, 
modulating its sensitivity and thus playing a role in the regulation of stress response. Further 
supporting this notion are studies showing that increased expression of the FKBP5 gene confers 
elevated GR resistance (Binder, 2009) and that glucocorticoids induce FKBP5 expression (Vermeer et 
al. 2003). Rats exposed to chronic mild stress show increased expression of FKBP5 as well as 
enhanced cytoplasmic levels of GR, primarily in ventral hippocampus and PFC. Chronic treatment 
with the antidepresant duloxetine is able to normalise such alterations (Guidotti et al. 2013). 
5.5.1. Genetic polymorphisms 
A number of studies reported an FKBP5 ฀ environment interaction in predicting the risk of 
depression, which is consistent with the observation that FKBP5 is responsive to stressor exposure 
and increases glucocorticoid levels by modulating GR sensitivity (Zannas and Binder 2014). More 
precisely, rs9296158, rs4713916, rs1360780, rs9470080 and rs3800373 have been found to be 
involved in gene ฀ childhood trauma interations, likely through mediating epigenetic modifications 
(see Section 4.5.2). The rs1360780 T allele was identified as the risk allele by three studies, the 
rs9470080 T allele by two studies, and the rs3800373 C allele by one study (Zannas and Binder 
2014). Some studies did not take into account FKBP5 ฀ environment interactions and three studies 
found that the rs1360780 T allele was associated with increased risk of depression (Lekman et al. 
2008; Lavebratt et al. 2010; Szczepankiewicz et al. 2014), two studies found an effect of rs4713916 
(Zobel et al. 2010; Szczepankiewicz et al. 2014), and non-replicated findings were reported for 
rs9470080, rs9296158 (Szczepankiewicz et al. 2014) and rs3800373 (Zobel et al. 2010). 
Despite controversial pharmacogenetic findings being reported for the FKBP5 gene, results obtained 
in a large sample of Caucasian subjects suggested that rs1360780, rs3800373, rs4713916 and 
rs352428 poly-morphisms may modulate antidepressant response (Fabbri and Serretti, 2015). The 
effect of rs3800373 and rs1360780 on antidepressant response was confirmed in subjects of 
Caucasian ethnicity by a recent meta-analysis (Niitsu et al. 2013). Interestingly, rs1360780 TT 
genotype showed FKBP5 protein levels that were twice as high as C allele carriers in vitro (Binder et 
al. 2004). This genotype was associated with faster response, modulation of FKBP5 expression, lower 
ACTH response in the combined dexamethasone-suppression/CRH-stimulation test and, 
hypothetically, a faster restoration of normal HPA axis function (Binder et al. 2004). Furthermore, 
rs352428 was demonstrated to be a functional polymorphism that may alter transcription factor 
binding (Ellsworth et al. 2013) and thus gene expression. 
5.5.2. Gene methylation 
DNA methylation in the rs1360780 region in intron 7 of FKBP5 showed a non-significant trend 
toward geno-type-dependent CpG methylation differences (hypomethylation) among subjects with a 
lifetime history of MDD (Hohne et al. 2015). Consistently, exposure to child abuse leads to a 
significant demethylation of CpGs in the functional glucocorticoid response elements (GREs) in 
intron 7 of the FKBP5 gene. Demethylation of these CpGs leads to an enhanced induction of FKBP5 
transcription by GR agonists and is associated with GR resistance (Klengel et al. 2013). The exposure 
to stressful events during childhood is hypothesised to induce local CpG demethylation mediated by 
GR binding to GREs, followed by a depressed transcriptional response to subsequent glucocorticoid 
exposure. Thus, stressor exposure results in higher cortisol release and GR activation in rs1360780 
risk allele carriers (Zannas and Binder, 2014). 
Of interest, the spindle and kinetochore complex subunit 2 (SKA2) protein is similar to FKBP51, in 
that it interacts with the GR. The C allele of the SKA2 genetic polymorphism rs7208505 (C/T) can be 
epigenetically modified via addition of a methyl group. The combination of genetic variation and 
epigenetic modification at rs7208505 has been associated with MDD and suicide and this finding has 
been replicated in both post-mortem brain tissue and peripheral blood samples (Guintivano et al. 
2014). 
5.5.3. Peripheral biomarkers 
In healthy subjects the rs1360780 CC genotype showed an increase of FKBP5 mRNA levels after 
stress exposure compared to CT or TT genotypes, despite no genotype effect on mRNA expression 
found in remitted MDD patients (Hohne et al. 2015). A reduction in FKBP5 mRNA levels after 8 
weeks of antidepressant treatment was associated with successful antidepressant response 
(Cattaneo et al. 2013). 
6. Clinical applications: pilot studies 
Evaluation of the reliability versus cost/effectiveness ratio of using biomarkers in clinical settings is a 
critical phase for the translation of research into tailored treatments. Studies are investigating the 
clinical usefulness of genetic testing for the prediction of antidepressant treatment outcome, in 
addition to serum-based tests analysing the expression levels of nine genes proposed for use in MDD 
diagnosis. Genetic tests for use in predicting antidepressant response include genes involved in 
antidepressant metabolism (the cytochrome P450 (CYP) superfamily; Porcelli et al. 2011), 
antidepressant transport (ABCB1) and antidepressant drug targets. For example, the GeneSight 
assay was designed to predict antidepressant response and side effects on the basis of poly-
morphisms in CYP2D6, CYP2C19, CYP2C9, CYP1A2, SLC6A4 and HTR2A. Patients classified as ‘‘at risk’’ 
according to this genetic test were reported to have 69% more total health care visits, 67% more 
general medical visits, greater than 3-fold more medical absence days, and greater than 4-fold more 
disability claims (Winner et al. 2013a). Furthermore, the GeneSight test was reported to double the 
likelihood of response compared to treatment as usual in a small prospective randomised double-
blind trial (Winner et al. 2013b) and similar findings were obtained in a larger open-label study (Hall-
Flavin et al. 2013). Finally, the GeneSight test was recently demonstrated to save $1,035.60 more in 
total medication costs (both CNS and non-CNS medications) over 1 year compared to a non-tested 
standard care cohort (Winner et al. 2015). In comparison, the commercial pharmacogenetic 
Genecept Assay includes polymorphisms in CYP2D6, CYP2C19, CYP3A4, SLC6A4, HTR2C, DRD2, 
CACNA1C, ANK3, COMT, MTHFR, MC4R, ADRA2A, BDNF, OPRM1 and GRIK1. This assay was tested in 
a naturalistic study (Brennan et al. 2015) that did not include a comparison arm receiving treatment 
as usual, thus statements regarding the clinical benefits of the test are particularly difficult. A study 
that did include patients treated as usual reported higher medication adherence and cost sav-ings in 
patients who underwent the test (Fagerness et al. 2014). Lastly, the CNSDose pharmacogenetic test 
includes polymorphisms in CYP2D6, CYP2C19, UGT1A1, ABCB1 and ABCC1 genes and in a rando-
mised trail patients receiving genotype-guided treatment showed a 2.52 greater probability of 
remission (Singh 2015). Of note, replication by the same investigators was found for the GeneSight 
test, but no inde-pendent validation of any of the above reported results was found. 
Two studies without commercial interest investigated the clinical benefits of a genotype-guided 
treatment versus treatment as usual. The first study investigated the clinical usefulness of 
polymorphisms in ABCB1, the gene encoding for the P-glycoprotein (or P-gp). P-gp is an ATP-
dependent drug efflux pump for xenobiotic compounds which limits uptake and accumulation of 
some lipophilic drugs (including several antidepressants) into the brain. In the genotype-guided 
treatment arm ABCB1 gene test results (rs2032583 and rs2235015 SNPs) were implemented into the 
clinical decision making process and this group showed higher remission rates and lower symptom 
severity at the time of discharge from hospital as compared to patients without ABCB1 testing 
(Breitenstein et al. 2014). Furthermore, antidepressant dose adjustments based on rs2032583 and 
rs2235015 were shown to affect antidepressant plasma concentration and symptom improvement 
in a consistent way (Breitenstein et al. 2016). A more recent study investigated the clinical 
usefulness of FKBP5 rs1360780 genotyping and it found that the risk allele showed a worse outcome 
in the treatment as usual arm compared to the genotyped-guided treatment arm (Stamm et al. 
2016). Unfortunately, these studies investigating ABCB1 poly-morphisms and FKBP5 rs1360780 
clinical usefulness lack independent replication and did not provide any cost/benefit ratio 
estimation. 
As reported above, a biomarker panel has been developed using serum-based testing to predict 
MDD. Results are interesting, but replication by independent groups is also lacking. The test includes 
nine bio-markers (alpha1 antitrypsin, apolipoprotein CIII, BDNF, cortisol, epidermal growth factor, 
myeloperoxidase, prolactin, resistin and soluble TNF-a receptor type II) and it demonstrated a 
sensitivity and specificity of 91.7 and 81% in differentiating between MDD and healthy controls, 
respectively (Papakostas et al. 2013). Similar findings were obtained in a further study by the same 
authors, with an overall test accuracy of 91–94%depending on the sample (Bilello et al. 2015). No 
replication by independent investigators is available. 
7. Innovative biomarkers and methodological strategies 
New research perspectives recently emerged in terms of both biomarker type and methodological 
approach. In particular, miRNAs were found to act as pivotal regulators of mRNA degradation and 
thus mRNA translation, providing complementary information to other biomarkers. miRNAs may 
also represent a relatively accessible method to therapeutically manipulate gene expression, making 
them particularly interesting targets for future treatments. Indeed miRNAs can be detected in body 
fluids such as blood and they show unexpected stability (Dwivedi 2016). For example, miR-16 was 
found to modulate SERT expression in different areas of the brain in response to antidepressants 
(Baudry et al. 2010). In mice fluoxetine was demonstrated to decrease the levels of miR-16 in the 
noradrenergic locus coeruleus and in the hippocampus, resulting in higher SERT expression in these 
areas, increased BDNF secretion and hippocampal neurogen-sis (Launay et al. 2011). In comparison, 
miR-135 has been reported to modulate SERT as well as HTR1A expression and its levels are 
increased in mice after the administration of antidepressants (Issler et al. 2014). Genetically 
modified mouse models, expressing higher or lower levels of miR-135, demonstrated major 
alterations in anxiety- and depression-like behaviours, 5-HT levels, and behavioural response to 
antidepressant treatment. Finally, miR-135a levels in blood and brain of depressed human patients 
were demonstrated to be lower compared to controls (Issler et al. 2014). A recent study including 
data on humans reported miR-1202 as a promising marker of MDD and antidepressant response 
(Lopez et al. 2014). Interestingly, the tar-gets of miR-1202 are genes involved in neurological 
processes associated with the pathogenesis of MDD, including the GRM4 gene that has been 
implicated in the regulation of anxiety-related behaviours (Pilc et al. 2008; Davis et al. 2012). Finally, 
a recent review reported a comprehensive overview in regard to miRNA in MDD and antidepressant 
treatment (Dwivedi 2016). 
Under the methodological point of view, PRS are worth note because they represent the most 
recent attempt to capture the complexity of disease traits, such as those found in MDD. PRS are 
obtained through the sum of the effect sizes of SNPs with a certain level of association with a 
particular trait. Thus, they attempt to classify patients within a risk spectrum, or in other words to 
assign to each patient a risk of developing the trait in question (i.e. response to a drug or disease 
status). 
Previous studies using this approach found that a genome-wide polygenic score was able to explain 
only small percentages of the variance in depression; for example, 1% was reported in elderly 
cohorts (Demirkan et al. 2011; Musliner et al. 2015) and 0.2%when considering a long-term average 
depression score (Chang et al. 2014). Phenotypic and environmental heterogeneity may explain 
these low percentages, but the available evidence excluded that stressful life events may interact 
with PRS associated with depression (Musliner et al. 2015). However, PRS were reported to have 
higher effect sizes as depressive symptom severity increased (Chang et al. 2014). Other possible 
sources of heterogeneity were not investigated. 
Genome-wide complex trait analysis is an alternative method that estimates the proportion of 
phenotypic variance on the basis of the genetic relatedness between individuals. Using this method, 
common variants were estimated to explain 42% of individual differences in antidepressant 
response and 43% when considering only SSRIs (Tansey et al. 2013). In contrast, a polygenic score 
based on a meta-analysis of the GENDEP and MARS projects predicted only between 0.5 and 1.2% of 
variance in improvement and remission in the STAR*D sample (GENDEP, MARS, STAR*D 
Investigators, 2013), suggesting a significant but not exciting overlap in terms of genetic variants 
involved across different MDD samples. 
8. Conclusion 
Several biomarkers of MDD and antidepressant response have been replicated at genetic, epigenetic 
and/or transcriptomic/proteomic levels (Table 1), despite controversial findings often being 
reported. Genes consistently found in the replicated studies (e.g., SLC6A4 and HTR2A) have been 
included in the first genetic tests investigated for clinical applicability (Table 2). It is important to 
underline that a favourable cost/benefit ratio has not been clearly demonstrated for any of the 
commercially available pharmacogenetic tests and currently no established clinical indications exist. 
The GeneSight test provided encouraging results, but the details regarding the algorithm used to 
classify patients according to their genotype were not published. Therefore, replication of the results 
by independent investigators has not been possible. The multi-assay, serum-based test that included 
nine bio-markers for MDD diagnosis (Papakostas et al. 2013) was performed on patients who already 
met the clinical DSM criteria for MDD, thus the cost/benefit balance of this test is not clear. 
Furthermore, the predictive properties of the serum-based test have not been replicated by an 
independent group of investigators. MDD may be too heterogeneous to be useful for the study of 
biomarkers. Given the broad nature of MDD, which most likely includes patients with many diverse 
aetiologies, it would be of interest to identify bio-marker panels to assist in identifying depression 
sub-types, such as melancholia or psychotic depression. Dimensional approaches to understand the 
risk and expression of mood disorders provide a different perspective for the development of future 
diagnostic/response-predictive tests. The Research Domain Criteria (Insel et al. 2010) focus on 
constructs under the negative valence systems domain (i.e., acute threat, potential threat, sustained 
threat, loss and frustrative non-reward) and provide dimensional criteria that are aimed at 
facilitating the identification of biomarkers of biologically homogeneous alterations that exist across 
disorders. As we specified in the Introduction, it is not always easy to distinguish between markers of 
acute depressive phases (markers of state) and markers of susceptibility to MDD, particularly for 
transcriptomic markers, and future studies investigating this issue are warranted. Finally, the 
integration of different types of biomarkers and the use of more complex multi-marker panels (that 
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